* LeMaitre Vascular Inc LMAT.OQ LMAT.O is expected
to show a
rise in quarterly revenue when it reports results on May 2 for
the period ending March 31 2024
* The Burlington Massachusetts-based company is expected to
report a 9.4% increase in revenue to $51.506 million from $47.08
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.The company's guidance on February
27 2024, for the period ended March 31, was for revenue between
50.50 million and 52.90 million.
* LSEG's mean analyst estimate for LeMaitre Vascular Inc is
for
earnings of 39 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months.
* Wall Street's median 12-month price target for LeMaitre
Vascular
Inc is $71.00, above its last closing price of $66.24.
The company's guidance on February 27 2024 for the period ended
March 31 was for Earnings before Interest and Taxes between 9.7
million and 11.3 million.The company's guidance on February 27
2024 for the period ended March 31 was for gross profit margin
of 68.5%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.36 0.36 0.38 Beat 6.4
Sep. 30 2023 0.30 0.30 0.33 Beat 9.1
Jun. 30 2023 0.32 0.32 0.36 Beat 13.8
Mar. 31 2023 0.25 0.25 0.27 Beat 7.4
Dec. 0.26 0.26 0.25 Missed -3.3
31 2022
Sep. 30 2022 0.27 0.28 0.25 Missed -9.9
Jun. 30 2022 0.27 0.27 0.16 Missed -39.6
Jan. 1 0001 0.28 0.28 0.27 Missed -2.6
This summary was machine generated April 30 at 21:57 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)